XKRX:326030 (Korea (the Republic of))
Â
Ordinary Shares
â‚©
104500.00
(-0.19%)
Dec 24
Business Description
SK Biopharmaceuticals Co Ltd
ISIN : KR7326030004
Share Class Description:
XKRX:326030: Ordinary SharesCompare
Compare
Traded in other countries / regions
326030.Korea IPO Date
2020-07-02Description
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.52 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.52 | |||||
| Debt-to-EBITDA | 2.43 | |||||
| Interest Coverage | 6.76 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 11.77 | |||||
| Beneish M-Score | -1.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 132.1 | |||||
| 3-Year EBITDA Growth Rate | 56.4 | |||||
| 3-Year EPS without NRI Growth Rate | 54.4 | |||||
| 3-Year FCF Growth Rate | 26.5 | |||||
| 3-Year Book Growth Rate | -9.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 34.77 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.84 | |||||
| 9-Day RSI | 52.29 | |||||
| 14-Day RSI | 50.36 | |||||
| 6-1 Month Momentum % | 25.03 | |||||
| 12-1 Month Momentum % | 2.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.63 | |||||
| Quick Ratio | 1.29 | |||||
| Cash Ratio | 0.79 | |||||
| Days Inventory | 799.28 | |||||
| Days Sales Outstanding | 85.13 | |||||
| Days Payable | 55.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -0.36 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.99 | |||||
| Operating Margin % | 13.78 | |||||
| Net Margin % | 11.22 | |||||
| FCF Margin % | 1.18 | |||||
| ROE % | 18.51 | |||||
| ROA % | 7.42 | |||||
| ROIC % | 14.55 | |||||
| ROC (Joel Greenblatt) % | 48.01 | |||||
| ROCE % | 11.88 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 142.76 | |||||
| Forward PE Ratio | 50.86 | |||||
| PE Ratio without NRI | 141.52 | |||||
| PS Ratio | 16.01 | |||||
| PB Ratio | 24.22 | |||||
| Price-to-Tangible-Book | 26.93 | |||||
| Price-to-Free-Cash-Flow | 1369.2 | |||||
| Price-to-Operating-Cash-Flow | 416.05 | |||||
| EV-to-EBIT | 147.15 | |||||
| EV-to-Forward-EBIT | 70.31 | |||||
| EV-to-EBITDA | 111.69 | |||||
| EV-to-Forward-EBITDA | 61.06 | |||||
| EV-to-Revenue | 15.83 | |||||
| EV-to-Forward-Revenue | 13.95 | |||||
| EV-to-FCF | 1344.34 | |||||
| Price-to-Graham-Number | 13.01 | |||||
| Price-to-Net-Current-Asset-Value | 71.55 | |||||
| Earnings Yield (Greenblatt) % | 0.68 | |||||
| FCF Yield % | 0.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SK Biopharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 511,327.566 | ||
| EPS (TTM) (â‚©) | 732 | ||
| Beta | 1.03 | ||
| Volatility % | 48.15 | ||
| 14-Day RSI | 50.36 | ||
| 14-Day ATR (â‚©) | 4194.612477 | ||
| 20-Day SMA (â‚©) | 103140 | ||
| 12-1 Month Momentum % | 2.03 | ||
| 52-Week Range (â‚©) | 72600 - 130000 | ||
| Shares Outstanding (Mil) | 78.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SK Biopharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SK Biopharmaceuticals Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
SK Biopharmaceuticals Co Ltd Frequently Asked Questions
What is SK Biopharmaceuticals Co Ltd(XKRX:326030)'s stock price today?
The current price of XKRX:326030 is â‚©104500.00. The 52 week high of XKRX:326030 is â‚©130000.00 and 52 week low is â‚©72600.00.
When is next earnings date of SK Biopharmaceuticals Co Ltd(XKRX:326030)?
The next earnings date of SK Biopharmaceuticals Co Ltd(XKRX:326030) is .
Does SK Biopharmaceuticals Co Ltd(XKRX:326030) pay dividends? If so, how much?
SK Biopharmaceuticals Co Ltd(XKRX:326030) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers